Imiglucerase

FDA warns of particulate contamination of Genzyme injectable products - MPR

empr.com — “The FDA and Genzyme have notified healthcare professionals about the potential for foreign particle contamination of certain lots of Cerezyme (imiglucerase), Fabrazyme (agalsidase beta), Myozyme (alglucosidase alpha), Aldurazyme (laronidase), and Thyrogen (thyrotropin alpha).” View full resource at empr.com

View Related
Share

Most Recently Shared on November 13, 2009 at 8:09 pm By:

MPR Medical Publisher

MPR News: FDA warns of particulate contamination of Genzyme injectable products: The FDA and Genzyme have notified ... http://bit.ly/1Vdhgj

News-Medical.Net Health News

Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV

buzzup.com — “Shire plc, the global specialty biopharmaceutical company, today presented positive data from a Phase III clinical trial (TKT-034) designed to evaluate the safety of switching to VPRIV (velaglucerase alfa for injection), from imiglucerase, as well as an interim analysis of safety data from an ongoing multicenter open-label treatment protocol (HGT-GCB-058) implemented to provide VPRIV to patients affected by the continuing shortage of imiglucerase.” View full resource at buzzup.com

View Related
Share

Most Recently Shared on March 26, 2010 at 11:39 am By:

Genetics News: Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who swit... http://buzzup.com/rnye

News-Medical.Net Health News

Genzyme third quarter revenue increases to $1.0 billion

news-medical.net — “Genzyme Corp. today reported third-quarter earnings growth driven by increased shipments of Cerezyme® (imiglucerase for injection). Patients in the United States began returning to normal dosing levels last month, and patients globally are expected to be able to do so this quarter. Earnings growth in the third quarter was also driven by strong revenue from Lumizyme" (alglucosidase alfa) and cost reduction measures.” View full resource at news-medical.net

View Related
Share

Most Recently Shared on October 21, 2010 at 4:53 am By:

Genzyme third quarter revenue increases to $1.0 billion: Genzyme Corp. today reported third-quarter earnings growt... http://bit.ly/bMBX7e

Genzyme Corporation Pharma

Genzyme Reports Financial Results for the Second Quarter of 2010

businesswire.com — “CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) today reported that second-quarter revenue was $1.08 billion, compared with $1.23 billion in the same period last year, reflecting limited shipments of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) due to product supply constraints in 2010. The company expects to be able to increase shipments of Cerezyme and Fabrazyme during the second half of the year. GAAP net income was $23,000, or $0.00 per dilu” View full resource at businesswire.com

View Related
Share

Most Recently Shared on July 21, 2010 at 2:08 pm By:

Genzyme Reports Financial Results for the Second Quarter of 2010 http://bit.ly/9lVns7

Genzyme Corporation Pharma

Genzyme Reports Financial Results for the First Quarter of 2010

businesswire.com — “CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) today reported that first-quarter revenue was $1.07 billion, compared with $1.15 billion in the same period last year, reflecting limited shipments of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) due to product supply constraints. GAAP net loss was $114.9 million, or $0.43 per diluted share, compared with net income of $195.5 million, or $0.70 per diluted share, in the first quarter of 2009. GAAP r” View full resource at businesswire.com

View Related
Share

Most Recently Shared on April 21, 2010 at 1:47 pm By:

Genzyme Reports Financial Results for the First Quarter of 2010: http://bit.ly/cUv1el

Drugs and Devices OW OW Health

Genzyme Successfully Meets First Milestones of FDA Consent Decree - Drugs.com MedNews

drugs.com — “All Filling and Finishing for U.S. Market Transferred Out of Allston Plant Nov 24, 2010 - Genzyme Corporation (NASDAQ GENZ) announced today that the company has” View full resource at drugs.com

View Related
Share

Most Recently Shared on November 24, 2010 at 4:09 pm By:

Genzyme Successfully Meets First Milestones of FDA Consent Decree: All Filling and Finishing for U.S. Mark... http://bit.ly/i9XrVb #drug

medical_tweets Health News

Shire Presents Positive New Data At The 60th Annual American Society Of Human Genetics (ASHG) For Patients With Type 1 Gaucher Disease

medicalnewstoday.com — “Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented positive new data from a Phase III clinical trial (study 039) designed to evaluate the efficacy of V” View full resource at medicalnewstoday.com

View Related
Share

Most Recently Shared on November 5, 2010 at 1:37 pm By:

Shire Presents Positive New Data At The 60th Annual American Society Of Human Genetics (ASHG) For Patients With Type 1 .. http://dld.bz/5dhh

News-Medical.Net Health News

Positive preliminary data from Protalix's taliglucerase alfa switchover trial for Gaucher disease

news-medical.net — “Protalix BioTherapeutics, Inc., announced today positive preliminary data from the first 15 patients that completed the Company's nine month, worldwide, multi-center, open-label, switchover trial of taliglucerase alfa for the treatment of Gaucher disease under a protocol cleared by the U.S. Food and Drug Administration (FDA). The data indicate that patients can safely be switched to taliglucerase alfa from imiglucerase (Cerezyme®).” View full resource at news-medical.net

View Related
Share

Most Recently Shared on November 2, 2010 at 8:41 am By:

Positive preliminary data from Protalix's taliglucerase alfa switchover trial for Gaucher disease: Protalix BioThe... http://bit.ly/b6mlb0